AKERO AK-US-001-0106 (AKERO 106) is a study that will be running in parallel with AKERO 105. This Phase 3 trial targets patients with compensated cirrhosis (F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (MASH). It will evaluate the efficacy of efruxifermin in improving liver function and reducing disease progression in cirrhotic patients who currently have limited treatment options. To participate in this trial, all individuals must meet the following criteria:
- Age 18 - 80 years
- BMI ≥ 25
- No history of decomposition or other liver diseases, HCC, and diabetes mellitus type 1 (DM1)
For Cohort 1, participants will need to provide a biopsy for evidence of MASH cirrhosis. For Cohort 2, participants need a kPa ≥ 20 OR ELF ≥ 10.5 and diabetes mellitus type 2 (DM2) OR 2x the metabolic risk factors
To learn more please email: kianakhbari@arizona.edu